Management of a 31-Year-Old Post-Fontan Patient with Hypoplastic Left Heart Syndrome
This patient requires structured surveillance in a specialized adult congenital heart disease (ACHD) center with annual comprehensive monitoring and a low threshold for advanced heart failure referral given their age and known risk of late circulatory failure.
Routine Surveillance Framework
Based on current guidelines, your 31-year-old patient likely falls into Physiological Stage B or C (depending on symptoms and functional status), requiring the following monitoring schedule 1:
Annual Assessments
- ACHD cardiologist visits: Every 6-12 months
- ECG and pulse oximetry: Every 6-12 months
- Transthoracic echocardiography: Annually
- 24-hour Holter monitoring: Annually to detect atrial arrhythmias
- Exercise testing: Every 12-24 months to assess functional capacity
- Cardiac MRI or CT: Every 24 months to evaluate for thrombosis, right-to-left shunts, ventricular function, and pathway obstruction 1
Biochemical Surveillance
Annual laboratory testing should include 1:
- Liver function tests (AST, ALT, bilirubin, albumin, INR)
- Renal function (creatinine, BUN, GFR)
- Complete blood count
- Brain natriuretic peptide (BNP)
Hepatic imaging (ultrasound, MRI, or CT) is reasonable given the high risk of Fontan-associated liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma at this age 1.
Medical Management
Anticoagulation Strategy
Anticoagulation with warfarin is mandatory if 1:
- History of documented thrombus or thromboembolic events
- Prior or current atrial arrhythmias
- Known intracardiac thrombus
If none of these apply, antiplatelet therapy (aspirin) or prophylactic anticoagulation may be considered, though evidence is less definitive 1.
Heart Failure Medications
While guidelines don't mandate specific heart failure therapy for asymptomatic patients, pulmonary vasoactive medications can improve exercise capacity 1. Consider:
- ACE inhibitors or ARBs for ventricular afterload reduction
- Pulmonary vasodilators (sildenafil, bosentan) if exercise limitation present
Red Flags Requiring Advanced Heart Failure Referral
The 2023 ACTION guidelines provide critical thresholds for when to refer to advanced heart failure specialists 2. Immediate referral is warranted for:
Cardiac/Ventricular Dysfunction
- Progressive systemic ventricular dysfunction on imaging
- Worsening systemic atrioventricular valve regurgitation
- Declining exercise capacity despite optimization
Fontan Pathway Dysfunction
- New or worsening cyanosis (oxygen saturation <90%)
- Evidence of pathway obstruction or significant collateral vessels
- Recurrent thrombosis despite anticoagulation
Lymphatic Dysfunction
- Protein-losing enteropathy (hypoalbuminemia, edema, diarrhea) - this is a Class IIa indication for transplant evaluation 1
- Plastic bronchitis
- Chylothorax
Extracardiac Dysfunction
- Progressive liver dysfunction or cirrhosis
- Renal impairment
- Recurrent hospitalizations
Arrhythmia Management
New or worsening atrial tachyarrhythmias mandate investigation for hemodynamic abnormalities 1. This requires:
- Comprehensive imaging (echo and likely cardiac MRI)
- Consider cardiac catheterization to assess hemodynamics
Treatment options include 1:
- Catheter ablation (Class IIa recommendation)
- Fontan revision surgery with arrhythmia surgery if recurrent despite medical therapy and ablation, particularly in older atriopulmonary connections with preserved ventricular function
When to Perform Cardiac Catheterization
Catheterization is reasonable when 1:
- Patient becomes symptomatic and noninvasive testing insufficient
- New atrial arrhythmias to assess hemodynamics
- Consideration of intervention or surgical revision
- May be reasonable even in asymptomatic patients to guide optimal therapy
Critical Pitfalls to Avoid
Delayed heart failure referral: Nearly one-third of Fontan patients die or require transplant within 35 years post-procedure 2. At 31 years post-Fontan, your patient is entering the highest-risk period.
Missing protein-losing enteropathy: This complication warrants transplant evaluation and has poor prognosis without intervention 1.
Inadequate liver surveillance: Fontan-associated liver disease is nearly universal and can progress to hepatocellular carcinoma 1.
Underestimating arrhythmia significance: Atrial arrhythmias often signal hemodynamic deterioration requiring investigation 1.
Perioperative risk: Any noncardiac surgery or procedure requires specialized anesthetic planning given the unique Fontan physiology 3.
The key principle is proactive surveillance with a low threshold for advanced heart failure consultation, as outcomes are significantly better with earlier rather than late referral 2.